Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hospital Corporation of China Limited

弘和仁愛醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 3869)

ANNOUNCEMENT ON CHANGE OF DIRECTORS

APPOINTMENT OF EXECUTIVE DIRECTOR

The board ("Board") of directors ("Directors", and each individually a "Director") of Hospital Corporation of China Limited (the "Company", together with its subsidiaries collectively, the "Group") hereby announces that pursuant to the Articles of Association ("Articles of Association") of the Company and upon recommendation made by the Nomination Committee ("Nomination Committee") of the Company, Ms. Pan Jianli (潘建麗女士) ("Ms. Pan") has been appointed as an Executive Director with effect from March 29, 2022. Her appointment will be reaffirmed at the annual general meeting to be held by the Company.

The biographical details of Ms. Pan and other information required to be disclosed under Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the "Listing Rules") are set out below:

Ms. Pan, aged 44, has been appointed as Chief Financial Officer of the Company in April 2021, and is currently responsible for overseeing the management of, among others, finance, investment and financing, risk control and audit work of the Company. Ms. Pan has over 20 years of working experience in financial management and investment areas, as well as extensive experience in various areas, including financial auditing, merger and acquisition, reorganization, crossborder investment and financing, of listed companies. From April 2007 to December 2017, Ms. Pan was an assistant to president, company secretary, person-in-charge of finance department and investment management department in China Glass Holdings Limited (03300.HK), a listed company in Hong Kong, and was responsible for, among others, capital operations, compliance, financial management and external audit of the listed company. From December 2017 until before joining the Company, she was a partner of a cross-border investment institution, responsible for cross-border merger and acquisition and financing advisory business based on the capital market of Hong Kong. Since December 6, 2019, Ms. Pan has been appointed as an independent nonexecutive director of China Singyes New Materials Holdings Limited (08073.HK), a company listed in Hong Kong, and has been serving as the chairman of the audit committee and a member of the remuneration committee of this company.

Ms. Pan currently serves as director for some subsidiaries of the Company, namely, Bliss Success Holdings Limited (妙榮控股有限公司), Impeccable Success Limited (成臻有限公司) and New Pride Holdings Limited (捷穎控股有限公司).

Ms. Pan obtained her master's degree in management from Guanghua School of Management, Peking University in the PRC in 2009 and her bachelor's degree in economics from Shandong University of Finance and Economics in the PRC in 1999. Ms. Pan is a Senior Accountant and a registered member of the Chinese Institute of Certified Public Accountants.

Ms. Pan has entered into a service contract with the Company in respect her appointment as Executive Director for an initial term of three years commencing from March 29, 2022, she is subject to retirement on rotation at least once for every three years and eligible for re-election at the annual general meeting in accordance with the Articles of Association of the Company,

As at the date of this announcement, Ms. Pan did not own or was not deemed to own any interest (as defined in Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong) in any shares or underlying shares of the Company. Ms. Pan will not receive any emoluments for her appointment as Executive Director.

Save as disclosed in this announcement, as at the date of this announcement, Ms. Pan (i) does not hold any positions in the Company or in the members of the Group; (ii) did not hold any directorship in other companies listed in Hong Kong or overseas within the past three years; and (iii) is not related to any director, senior management, substantial shareholders or controlling shareholders (as defined respectively in the Listing Rules) of the Company.

Save as disclosed in this announcement, as at the date of this announcement, no other information in connection with the appointment of Ms. Pan is required to be disclosed pursuant to Rules 13.51(2)(h) to (v), nor any other matters are required to be brought to the attention of the shareholders of the Company.

The Board would like to extend its warm welcome to the appointment of Ms. Pan.

RETIREMENT OF NON-EXECUTIVE DIRECTOR AND MEMBER OF THE AUDIT COMMITTEE

The Board hereby announces that Ms. Shi Wenting (石文婷女士) ("Ms. Shi") has resigned from the positions of non-executive Director of the Company and member of the Audit Committee ("Audit Committee") of the Company with effect from March 29, 2022 due to other work commitments.

Ms. Shi has confirmed that she did not have any disagreements with the Board, nor any other matters related to her resignation are required to be brought to the attention of the shareholders of the Company.

The Board would like to express our gratitude for Ms. Shi's contribution to the Group.

APPOINTMENT OF MEMBER OF THE AUDIT COMMITTEE

The Board further announces that Mr. Dang Jinxue (党金雪先生) ("Mr. Dang"), an independent non-executive Director of the Company, has been appointed as a member of the Audit Committee of the Company with effect from March 29, 2022.

By order of the Board
Hospital Corporation of China Limited
Chen Shuai
Chairman

Beijing, China, March 29, 2022

As at the date of this announcement, the Directors of the Company are Mr. CHEN Shuai, Mr. LU Wenzuo, Mr. Pu Chengchuan and Ms. Pan Jianli being the executive Directors; Ms. LIU Lu and Ms. WANG Nan being the non-executive Directors; and Mr. DANG Jinxue, Mr. SHI Luwen and Mr. ZHOU Xiangliang being the independent non-executive Directors.